Minisymposium: Biomarkers in Drug Discovery – How to Predict for Success in the Clinic
The SciLifeLab Drug Discovery and Development platform and AstraZeneca jointly welcome you to Biomarkers in Drug Discovery – How to Predict for Success in the Clinic. Registration is open!
Venue Universitetshuset, Room IX, Biskopsgatan 3, Uppsala
Time 8 November 2018, 10am–4pm
Registration & Information SciLifeLab Events
Contact Kristian Sandberg, SciLifeLab
Biomarkers in Drug Discovery
Biomarkers have influence on understanding of disease mechanism, optimize the chance for successful patients’ selection and outcomes of clinical trials and thus may contribute to minimizing cost of a drug development. In drug discovery, the accompanying discovery of potential biomarkers and the subsequent development as tools to identify patients that can benefit from treatment and to demonstrate a pharmacological response to the exploratory drug are therefore of increasing importance. In this minisymposium, we gather international academic and industrial experts to review state-of-the-art and new initiatives. Please, take the chance to discuss your own project with the speakers during the day.
Preliminary Programme
10:00 Introduction
Kristian Sandberg, SciLifeLab/DDD
Anna Sandström, AstraZeneca
10:15 Biomarkers in 21st Century Drug Development
Virginia Byers Kraus, MD, PhD (Durham, North Carolina, US)
11:00 Transforming Drug Research and Development with Genomics
Carolina Haefliger, MD, AstraZeneca VP, Head of CVRM Precision Medicine
11:30 Turning a biomarker candidate into a diagnostic for clinical use
Joachim Reischl, AstraZeneca VP, Head of Policy, Portfolio & Externalisation
12:00 Lunch and mingle
13:00 Rigging diagnostics for new predictive biomarkers – the Genomic Medicine Sweden initiative
Johan Botling, MD, PhD, Uppsala University
13:30 Truly Translational – helping the small to think big. Biomarker strategies for SME’s
Karin von Wachenfeldt, PhD, CEO Truly Translational Sweden AB
14:00 SCAN-B: transcriptome profiling of early breast cancer for identification of patients that may benefit from treatment
Åke Borg, PhD, Lund University
14:30 Coffee and mingle
15:00 Biomarkers in the development of KAND567 in acute myocardial infarction
Niclas Brynne, PhD, Chief Development officer at Kancera
15:30 Panel discussion and concluding remarks
Arr. SciLifeLab Drug Discovery and Development platform, AstraZeneca